DMD Noab BioDiscoveries

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on April 17, 2008; DOI: 10.1124/dmd.107.018267
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Christopher, L. J.
Right arrow Articles by Iyer, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Christopher, L. J.
Right arrow Articles by Iyer, R.


Received for publication August 13, 2007.
Revised April 15, 2008.
Accepted for publication April 16, 2008.

METABOLISM AND DISPOSITION OF DASATINIB AFTER ORAL ADMINISTRATION TO HUMANS

Lisa J. Christopher 1, Donghui Cui 1, Chiyuan Wu 1, Roger Luo 1, James A. Manning 1, Samuel J. Bonacorsi 1, Michael Lago 1, Alban Allentoff 1, Francis Y. F. Lee 1, Betty McCann 1, Susan Galbriath 1, Donald P Reitberg 2, Kan He 1, Anthony Barros Jr. 1, Anne Blackwood Chirchir 1, W Griffith Humphreys 1, Ramaswamy Iyer 1*

1 Bristol-Myers Squibb Co. 2 Bristol-Myers Squibb

* Address correspondence to: E-mail: ramaswamy.iyer{at}bms.com

Abstract

SPRYCEL® (Dasatinib, BMS-354825), a multiple kinase inhibitor, is currently approved to treat chronic myelogenous luekemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) tumors in patients that are resistant or intolerant to imatinib mesylate (Gleevec®). After a 100 mg single oral dose of [14C]dasatinib to healthy volunteers, the radioactivity was rapidly absorbed (Tmax {approx}0.5 h). Both dasatinib and total radioactivity (TRA) plasma concentrations declined rapidly with elimination half-life values of <4 h. Dasatinib was the major drug-related component in human plasma. At 2 h, dasatinib accounted for 25% of the TRA in plasma suggesting that metabolites contributed significantly to the total drug-related component. There were many circulating metabolites detected that included hydroxylated metabolites (M20 and M24), an N-dealkylated metabolite (M4), an N-oxide (M5), an acid metabolite (M6), glucuronide conjugates (M8a,b) and products of further metabolism of these primary metabolites. Most of the administered radioactivity was eliminated in the feces (85%). Urine recovery accounted for <4% of the dose. Dasatinib accounted for <1% and 19% of the dose in urine and feces, respectively, suggesting that dasatinib was well absorbed after oral administration and extensively metabolized prior to being eliminated from the body. The exposures of pharmacologically active metabolites M4, M5, M6, M20 and M24 in patients, along with their cell-based IC50 for Src and Bcr-Abl kinase inhibition, suggested that these metabolites were not expected to contribute significantly towards in vivo activity.


Key words: anticancer agents, cytochrome P450 catalyzed oxidations, drug clearance, drug development, drug disposition, human pharmacokinetics, mass spectrometry, metabolite identification, metabolite kinetics, pharmacokinetics




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.